Your browser doesn't support javascript.
Cerebral venous thrombosis in COVID-19.
Ghosh, Ritwik; Roy, Dipayan; Mandal, Arpan; Pal, Shyamal Kanti; Chandra Swaika, Bikash; Naga, Dinabandhu; Pandit, Alak; Ray, Biman Kanti; Benito-León, Julián.
  • Ghosh R; Department of General Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, India.
  • Roy D; Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.
  • Mandal A; Department of General Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, India.
  • Pal SK; Department of General Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, India.
  • Chandra Swaika B; Department of General Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, India.
  • Naga D; Department of General Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, India.
  • Pandit A; Bangur Institute of Neurosciences, Kolkata, West Bengal, India.
  • Ray BK; Bangur Institute of Neurosciences, Kolkata, West Bengal, India.
  • Benito-León J; Department of Neurology, University Hospital "12 de Octubre", Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Department of Medicine, Universidad Complutense, Madrid, Spain. Electronic address: jbenitol67@gmail.com.
Diabetes Metab Syndr ; 15(3): 1039-1045, 2021.
Article in English | MEDLINE | ID: covidwho-1303499
ABSTRACT
BACKGROUND AND

AIMS:

Initially, novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) was considered primarily a respiratory pathogen. However, with time it has behaved as a virus with the potential to cause multi-system involvement, including neurological manifestations. Cerebral venous sinus thrombosis (CVT) has increasingly been reported in association with coronavirus infectious disease of 2019 (COVID-19). Here, we have shed light upon CVT and its possible mechanisms in the backdrop of the ongoing COVID-19 pandemic.

METHODS:

In this review, data were collected from PubMed, EMBASE and Web of Science, until March 30, 2021, using pre-specified searching strategies. The search strategy consisted of a variation of keywords of relevant medical subject headings and keywords, including "COVID-19", "SARS-CoV-2", "coronavirus", and "cerebral venous sinus thrombosis".

RESULTS:

COVID-19 has a causal association with a plethora of neurological, neuropsychiatric and psychological effects. CVT has gained particular importance in this regard. The known hypercoagulable state in SARS-CoV-2 infection is thought to be the main mechanism in COVID-19 related CVT. Other plausible mechanisms may include vascular endothelial dysfunction and altered flow dynamics.

CONCLUSIONS:

Although there are no specific clinical characteristics, insidious or acute onset headache, seizures, stroke-like, or encephalopathy symptoms in a patient with, or who has suffered COVID-19, should prompt the attending physician to investigate for CVT. The treatment of COVID-19 associated CVT does not differ radically from the therapy of CVT without the infection, i.e. urgent initiation of parenteral unfractionated heparin or low molecular weight heparin followed by conventional or mostly newer oral anticoagulants.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Intracranial Thrombosis / COVID-19 Type of study: Observational study / Prognostic study / Reviews Topics: Long Covid Limits: Humans Language: English Journal: Diabetes Metab Syndr Year: 2021 Document Type: Article Affiliation country: J.dsx.2021.04.026

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Intracranial Thrombosis / COVID-19 Type of study: Observational study / Prognostic study / Reviews Topics: Long Covid Limits: Humans Language: English Journal: Diabetes Metab Syndr Year: 2021 Document Type: Article Affiliation country: J.dsx.2021.04.026